Lipella Pharmaceuticals to publish abstract on preclinical support for LP-50

Lipella Pharmaceuticals announces that its abstract has been accepted for the 2024 American Society of Clinical Oncology meeting on May 31 through June 4 in Chicago, Illinois. Lipella’s abstract, “Intravesical local administration of pembrolizumab for treatment of bladder cancer: A novel strategy to minimize toxicity” will be published at www.asco.org/abstracts. Dr. Jonathan Kaufman, CEO of Lipella, said, “ASCO’s 2024 meeting is the ideal venue for dissemination of our recent progress in the treatment of bladder cancer. Lipella’s new product candidate, LP-50, is intended to be indicated for non-muscle invasive bladder cancer. Our abstract includes preclinical data demonstrating the efficacy of intravesical pembrolizumab in mice, including size-reduction in bladder tumors measured via T2 weighted MRI.”